Cellebrite DI (CLBT) Expected to Release Earnings on Thursday

Cellebrite DI (NASDAQ:CLBT) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Cellebrite DI to post earnings of $0.0940 per share and revenue of $145.83 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock opened at $12.64 on Wednesday. The firm has a market cap of $3.15 billion, a PE ratio of 45.36, a price-to-earnings-growth ratio of 1.95 and a beta of 1.06. The firm’s 50-day simple moving average is $11.61 and its 200-day simple moving average is $13.29. Cellebrite DI has a 1 year low of $9.58 and a 1 year high of $19.98.

Insider Buying and Selling at Cellebrite DI

In other news, CMO David Gee sold 4,323 shares of Cellebrite DI stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $11.36, for a total value of $49,109.28. Following the completion of the transaction, the chief marketing officer directly owned 135,281 shares of the company’s stock, valued at approximately $1,536,792.16. The trade was a 3.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO David Barter sold 12,134 shares of Cellebrite DI stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $11.21, for a total transaction of $136,022.14. Following the completion of the transaction, the chief financial officer directly owned 322,085 shares of the company’s stock, valued at $3,610,572.85. This trade represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 56,516 shares of company stock valued at $636,660 over the last three months. 5.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

CLBT has been the subject of a number of research reports. DA Davidson reiterated a “buy” rating and issued a $15.00 price target on shares of Cellebrite DI in a research note on Tuesday, September 15th. Weiss Ratings lowered Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 27th. JPMorgan Chase & Co. cut their price objective on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Needham & Company LLC reduced their target price on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, Lake Street Capital reduced their target price on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.70.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.